AB1102 A RARE CASE OF ACUTE INFLAMMATORY DEMYELINATING POLYRADICULOPATHY FOLLOWING THE SECOND DOSE OF PFIZER COVID-19 VACCINE

Background We present a case of 36 year-old female who developed Acute Immune-mediated Demyelinating Polyneuropathy (AIDP) after receiving the second dose Pfizer COVID-19 vaccine. Objectives To report rare auto-immune complication COIVD-19 vaccination. educate and inform physicians about approach to diagnosing AIDP narrowing down its etiology. Methods Case literature review Results A with no significant past medical history presented hospital progressive bilateral paresthesia. She started experience numbness tingling sensation in her extremities 1 week Following 5 days symptoms onset, she was longer able hold onto objects experienced difficulty ambulating without assistance. Physical exam notable for decreased distal touch pain all 4 limbs, otherwise, rest neurological musculoskeletal evaluation normal. MRI-head showed small scattered foci increased FLAIR signal white matter, suggesting an underlying inflammatory process. Electromyography (EMG) performed evidence acute diffuse sensorimotor neuropathy mixed axonal demyelinating features. These results along clinical features allowed us diagnose our patient (AIDP). Extensive autoimmune workup, including anti-GM1, GD1b, Gq1b, ANA, DS-DNA, RF, CCP, C/P ANCA, were unremarkable. had positive anti-Ro atb but did not have any or physical that would suggest Sjogren’s Syndrome. Vitamin levels (B12, folate, thiamine) found be Infectious workup serum CSF which included hepatitis serologies, Campylobacter jejuni serology, Lyme atb, CMV EBV negative. The possible etiology disease attributed vaccine given temporal correlation. subsequently treated 6 cycles IVIG resulted moderate symptomatic improvement. Conclusion is autoimmune-guided result degeneration myelinated nerves [1]. In some extremely cases, molecular mimicry following vaccination may lead this There been reports linked Johnson & AstraZeneca vaccines [2]. Recently, few cases also observed [2-3]. Interestingly, majority these occurred first vaccine, making even more peculiar as should made aware potential Given extreme rarity it important note common infectious investigated before attributing causal relationship vaccines. References [1]Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet 2021. doi:10.1016/S0140-6736(21)00517-1 [2]Bouattour, N., Hdiji, O., Sakka, syndrome Pfizer-BioNTech vaccine: reported cases. Neurol Sci doi:10.1007/s10072-021-05733-x [3]Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological Complications COVID-19: Guillain-Barre Syndrome Vaccine. Cureus doi:10.7759/cureus.13426 Disclosure Interests None declared